Differential microRNA expression profiles in tamoxifen-resistant human breast cancer cell lines induced by two methods

Oncology Letters
Peng YeXinghua Long

Abstract

Tamoxifen (TAM) resistance has become a severe problem for endocrine therapy of breast cancer. The present study investigated the association between microRNA (miRNA) expression and TAM resistance in breast cancer. The TAM-resistant breast cancer MCF-7C and MCF-7T cell lines were established using the human breast cancer cell line MCF-7 as the parental cell line and 4-hydroxytamoxifen (OHT) as the screening drugin vitro. The MCF-7C cell line was established by dose stepwise induction beginning with a low concentration of OHT; the MCF-7T cell line was established by temporal stepwise induction beginning with a high concentration of OHT. Differential miRNA expression profiles between TAM-sensitive (MCF-7) and TAM-resistant (MCF-7C and MCF-7T) breast cancer cell lines were detected and analyzed using RNA sequencing technology. The results of western blot analysis indicated that the level of ERα protein expression in drug-resistant cells was significantly increased. A total of 1,646 miRNAs were detected in all samples, including 1,376 known miRNAs and 270 predicted miRNAs. There were 118 miRNAs expressed at significantly different levels between MCF-7C and MCF-7 cells (P<0.05); among them, 67 miRNAs were upregulated (P<0.05) and 51...Continue Reading

References

Apr 2, 2004·Nature Reviews. Cancer·Mary Ann Jordan, Leslie Wilson
Sep 17, 2004·Nature·Victor Ambros
Aug 17, 2005·Cancer Research·Marilena V IorioCarlo M Croce
Nov 10, 2006·Cancer Chemotherapy and Pharmacology·Scott M Hammond
Jan 12, 2008·Molecular Cancer Therapeutics·Paul E BlowerWolfgang Sadee
Aug 19, 2008·The Journal of Biological Chemistry·Tyler E MillerSarmila Majumder
Oct 29, 2008·Genome Research·Robin C FriedmanDavid P Bartel
Mar 7, 2009·Nucleic Acids Research·Nalinie S WickramasingheCarolyn M Klinge
May 8, 2009·The Journal of Biological Chemistry·Tzu-Hsuan HuangMichael T McManus
Aug 25, 2009·Nature Reviews. Cancer·Elizabeth A Musgrove, Robert L Sutherland
Dec 22, 2010·Molecular Cancer·Diana M CittellyFrank E Jones
Aug 9, 2011·Archives of Medical Research·Zhao-Xia WangYong-Mei Yin
Nov 18, 2011·Molecular Biology International·Nicole Rusca, Silvia Monticelli
Jun 15, 2012·BMC Cancer·Zeinab BarekatiXiao Yan Zhong
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Oct 1, 2013·The Breast : Official Journal of the European Society of Mastology·James N Ingle
Jul 17, 2014·Nature Reviews. Molecular Cell Biology·Minju Ha, V Narry Kim
Jul 30, 2014·MicroRNA·Sarah Bajan, Gyorgy Hutvagner
Aug 12, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Guoqiang ZhangZhenlin Yang
Dec 30, 2014·Clinical Biochemistry·Shaymaa M M Yahya, Ghada H Elsayed
Oct 22, 2015·Breast Cancer Research and Treatment·Andrew CiupekSuzanne A W Fuqua
Jul 9, 2016·Journal of Cancer·Yue LiXiaoning Peng
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Jan 23, 2021·Journal of Mammary Gland Biology and Neoplasia·Nina PetrovićMilica Nedeljković
Aug 8, 2021·Cancers·Jéssica Fernanda BarazettiJaqueline Carvalho de Oliveira
Oct 1, 2021·Frontiers in Oncology·Jin-Hai TianLi-Bin Wang

❮ Previous
Next ❯

Methods Mentioned

BETA
2500 sequencing
immunoprecipitation assay
X-ray

Software Mentioned

TMeV
miRDeep2
SPSS
AlphaEaseFC
EBseq R package

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Nan fang yi ke da xue xue bao = Journal of Southern Medical University
Xiu-ying CuiHe-rui Yao
Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban
Gaopeng LiLu Ye
© 2022 Meta ULC. All rights reserved